Literature DB >> 2463912

N,N dimethylglycine and epilepsy.

G Gascon1, B Patterson, K Yearwood, H Slotnick.   

Abstract

Nineteen institutionalized patients with frequent seizures (group average two to three per day; seizure types--generalized, akinetic/myoclonic), were treated randomly with either placebo or N,N dimethylglycine (DMG) for 28 days. Dosage was 300 mg/day for the first 14 days and then 600 mg/day. Plasma levels were measured at baseline, days 2, 5, 8, 15, 22, 30, and 1 and 2 weeks after the study ended. No differences in seizure frequency were noted between placebo and DMG or between baseline and test conditions. No toxicity was noted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463912     DOI: 10.1111/j.1528-1157.1989.tb05288.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder.

Authors:  W M Bolman; J A Richmond
Journal:  J Autism Dev Disord       Date:  1999-06

Review 2.  A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.

Authors:  Richard E Frye; Daniel Rossignol; Manuel F Casanova; Gregory L Brown; Victoria Martin; Stephen Edelson; Robert Coben; Jeffrey Lewine; John C Slattery; Chrystal Lau; Paul Hardy; S Hossein Fatemi; Timothy D Folsom; Derrick Macfabe; James B Adams
Journal:  Front Public Health       Date:  2013-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.